EVAX Q4 2023 Earnings — Evaxion Biotech A/S Revenue & Financial Results | Market Cap Arena

EVAXEvaxion Biotech A/S

$20M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$73,000

Gross Profit

$73,000100.0% margin

Operating Income

-$4M-5978.1% margin

Net Income

-$5M-6195.9% margin

EPS (Diluted)

$-6.60

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

-$21,000

Balance Sheet

Total Assets

$13M

Total Liabilities

$18M

Stockholders' Equity

-$5M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73,000	$0	—
Gross Profit	$73,000	$0	—
Operating Income	-$4M	-$7M	+33.1%
Net Income	-$5M	-$7M	+34.2%